Therapy News and Research

RSS

Onconova, SymBio enter commercialization collaboration for rigosertib in Japan and Korea

Onconova Therapeutics, Inc., and SymBio Pharmaceuticals Limited announced today that they will collaborate to develop and commercialize rigosertib in Japan and Korea. Onconova is conducting late-stage clinical trials with rigosertib (ON 01910.Na) in the U.S., Europe and India for the treatment of Myelodysplastic Syndromes (MDS) and solid tumors.

8 Jul 2011

AJMS summarizes developments related to idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a common and severe lung disease of unknown cause and with no proven therapies. But researchers are pushing forward in investigating new clues to the development and effective treatment of IPF, according to a special symposium presented in The American Journal of the Medical Sciences (AJMS), official journal of the Southern Society for Clinical Investigation (SSCI).

8 Jul 2011

First dog enters ADXS-HER2 dose-ranging study in canine osteosarcoma

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announces that the first dog has entered a dose-ranging in canine osteosarcoma at the University of Pennsylvania School of Veterinary Medicine.

8 Jul 2011

Study finds higher rate of switching from Byetta to Victoza in treatment of type 2 diabetes

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that although Amylin/Eli Lilly's Byetta currently commands a higher patient share than Novo Nordisk's Victoza, more patients were switched from Byetta to Victoza than vice versa (25.2 percent versus 2.8 percent) in the last quarter of 2010 among recently treated type 2 diabetes patients.

8 Jul 2011

Transplants with half-matched bone marrow or cord blood are comparable to fully matched tissue

Identifying a suitable donor for leukemia and lymphoma patients who need bone marrow transplants may be far easier now that results of two clinical trials show transplant results with half-matched bone marrow or umbilical cord blood are comparable to fully matched tissue, thanks in large part to the availability of effective antirejection drugs and special post-transplant chemotherapy.

8 Jul 2011

New technique may help scientists probe mysteries of many different stem cells

Researchers at the Salk Institute have been able to genetically incorporate "unnatural" amino acids, such as those emitting green fluorescence, into neural stem cells, which then differentiate into brain neurons with the incandescent "tag" intact.

8 Jul 2011

Mesenchymal stem cells protect and heal

A stem cell that can morph into a number of different tissues is proving a natural protector, healer and antibiotic maker, researchers at Case Western Reserve University and their peers have found.

8 Jul 2011

New target could halt growth of glioblastoma

Researchers have uncovered a new target that could stop the growth of glioblastoma, a deadly form of brain cancer.

8 Jul 2011

Collaborative research discovers broadly acting antibody against influenza viruses

Annually changing flu vaccines with their hit-and-miss effectiveness may soon give way to a single, near-universal flu vaccine, according to a new report from scientists at The Scripps Research Institute and the Dutch biopharmaceutical company Crucell. They describe an antibody that, in animal tests, can prevent or cure infections with a broad variety of influenza viruses, including seasonal and potentially pandemic strains.

8 Jul 2011

Medtronic enters definitive agreement to acquire Salient Surgical Technologies

Medtronic, Inc. today announced that it has entered into a definitive agreement to acquire Salient Surgical Technologies, Inc., the leader in the advanced energy category for haemostatic sealing of soft tissue and bone in a variety of surgical procedures including orthopaedic surgery, spine, open abdominal and thoracic procedures.

From Medtronic 8 Jul 2011

Half-matched transplants widen donor pool for leukemia and lymphoma

7 Jul 2011

Experiment to protect astronauts from bone loss during space travel

Astronauts lose a significant amount of bone mass during space travel and with long duration flights there is concern that this bone loss could lead to an increased risk of fractures.

7 Jul 2011

Cultural, gender and ethnic stereotypes can distort treatment of Parkinson's

Cultural, ethnic and gender stereotypes can significantly distort clinical judgments about "facially masked" patients with Parkinson's disease, according to a newly published study from researchers at Tufts University, Brandeis University and the National Cheng Kung University in Taiwan.

7 Jul 2011

Study finds link between genetic variation and cetuximab rectal cancer therapy

team of researchers led by Keck School of Medicine of the University of Southern California (USC) oncologist Heinz-Josef Lenz, M.D., has identified a genetic marker that may predict which patients with rectal cancer can be cured by certain chemotherapies when combined with surgery.

7 Jul 2011

Gene therapy may help prevent progression of type 1 diabetes

Increasing a specific protein in areas of the pancreas that produce insulin blocks the immune attack that causes type 1 diabetes, researchers reported in the August issue of the Journal of Clinical Investigation, published early online.

7 Jul 2011

Improved global safety monitoring of HIV drugs is needed

With at least five million people worldwide taking antiretroviral therapy for HIV infection, the International Forum for Collaborative HIV Research, in a PLoS Medicine Policy Forum published on Tuesday, "recommends that improved and sustained global drug safety monitoring, including monitoring for substandard products, drug diversion, inappropriate use, and toxicity, is critical," a press release from PLoS states.

7 Jul 2011

Amrubicin vs. topotecan Phase III trial against lung cancer presented at IASLC conference

Lung cancer patients given amrubicin (Calsed) as a second-line therapy had a significantly improved response rate and longer progression-free survival than patients treated with topotecan (Hycamtin), according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer.

7 Jul 2011

TGen presents two key studies at 14th World Conference on Lung Cancer

The Translational Genomics Research Institute (TGen) is presenting two key studies, including one today, at the 14th World Conference on Lung Cancer, July 3-7 in Amsterdam.

7 Jul 2011

Eighteen scientists receive Damon Runyon Cancer Research Foundation awards

The Damon Runyon Cancer Research Foundation, a non-profit organization focused on supporting innovative early career researchers, named 18 new Damon Runyon Fellows at its spring Fellowship Award Committee review.

7 Jul 2011

Toxic waste exposure impacts residents' health in Campania Region

Scientific evidence is mounting in support of a significant increase in cancer mortality and malformations occurring in specific areas of the Campania Region of Southern Italy, where improper waste management and illegal waste trafficking have been repeatedly documented, according to "Wasting lives: the effects of toxic waste exposure on health.

7 Jul 2011